Efficacy and safety of pioglitazone, empagliflozin and glimepiride as third‐line agents in patients with type 2 diabetes inadequately controlled with metformin and DPP ‐4 inhibitors: A multicentre, phase 4 randomized controlled trial
Diabetes, Obesity and Metabolism · 2025-11 · 27 (11) · 6375-6385
DOI: 10.1111/dom.70030 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 14.08.2025. Verfasst von Yun Kyung Cho und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Sulfonylurea Compounds, Benzhydryl Compounds, Glucosides. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Yuhan.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims
To assess the efficacy and safety of three triple‐combination therapies in patients with type 2 diabetes (T2D) inadequately controlled on metformin and a dipeptidyl peptidase‐4 (DPP‐4) inhibitor. Materials and methods This multicentre, prospective, randomised, open‐label, parallel‐group, phase 4 study included patients with T2D inadequately controlled on metformin (≥1000 mg) and a DPP‐4 inhibitor. Participants were randomised to receive empagliflozin 10 mg/day ( n = 61), pioglitazone 15 mg/day ( n = 58) or glimepiride 2 mg/day ( n = 57). The primary outcome was glycated haemoglobin (HbA1c) level change after 24 weeks of treatment.
Results
The mean age, HbA1c level and diabetes duration of the patients were 58.5 ± 10.0 years, 7.8 ± 0.7% and 8.1 ± 5.6 years, respectively. HbA1c level decreased after treatment (−0.78 ± 0.09, empagliflozin; −0.89 ± 0.09, pioglitazone; and −0.93 ± 0.12 glimepiride). No significant differences were observed in HbA1c reduction among the three triple‐combination therapies. The proportions of patients with HbA1c < 7.0% were similar across the three regimens (65.6%, empagliflozin; 56.9%, pioglitazone; and 63.2%, glimepiride). Significant weight loss was observed in the empagliflozin group (−1.73 ± 3.14 kg), whereas weight gain was observed in the pioglitazone and glimepiride groups (1.11 ± 3.97 kg and 1.11 ± 4.07 kg, respectively). The glimepiride group reported four hypoglycaemic episodes (6.56%), while none were reported in the other groups.
Conclusions
The addition of empagliflozin, pioglitazone, or glimepiride to metformin and DPP‐4 inhibitors significantly improved glycaemic control in patients with T2D. The selection of a third agent should be individualized based on the patient characteristics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
- Asan Diabetes Center, Asan Medical Center, Seoul, Republic of Korea.
- Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
- Department of Internal Medicine, Hanyang University Guri Hospital, Hanyang University College of Medicine, Guri, Republic of Korea.
- Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Republic of Korea.
- Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.
ORCID-Profile: Byung-Wan Lee, Sung Wan Chun, You-Cheol Hwang, Woo Je Lee
Förderung
- Yuhan
Zitieren
APA
Cho, Y. K., Cho, J. H., Hong, S. M., Park, J. H., Lee, B. W., Yoo, J. H., Kim, J. H., Chun, S. W., Hwang, Y. C., Song, K. H., & Lee, W. J. (2025). Efficacy and safety of pioglitazone, empagliflozin and glimepiride as third‐line agents in patients with type 2 diabetes inadequately controlled with metformin and DPP ‐4 inhibitors: A multicentre, phase 4 randomized controlled trial. Diabetes, Obesity and Metabolism, 27(11), 6375-6385. https://doi.org/10.1111/dom.70030
Vancouver
Cho YK, Cho JH, Hong SM, Park JH, Lee BW, Yoo JH, et al. Efficacy and safety of pioglitazone, empagliflozin and glimepiride as third‐line agents in patients with type 2 diabetes inadequately controlled with metformin and DPP ‐4 inhibitors: A multicentre, phase 4 randomized controlled trial. Diabetes, Obesity and Metabolism. 2025;27(11):6375-6385. doi:10.1111/dom.70030
BibTeX
@article{Cho2025,
author = {Cho, Yun Kyung and Cho, Jae-Hyoung and Hong, Sang-Mo and Park, Jung Hwan and Lee, Byung-Wan and Yoo, Jee Hee and Kim, Jae Hyeon and Chun, Sung Wan and Hwang, You-Cheol and Song, Kee-Ho and Lee, Woo Je},
title = {Efficacy and safety of pioglitazone, empagliflozin and glimepiride as third‐line agents in patients with type 2 diabetes inadequately controlled with metformin and DPP ‐4 inhibitors: A multicentre, phase 4 randomized controlled trial},
journal = {Diabetes, Obesity and Metabolism},
year = {2025},
volume = {27},
number = {11},
pages = {6375--6385},
doi = {10.1111/dom.70030}
}
EUVIMED